|
2023
|
Invention
|
Treatment of myasthenia gravis with zilucoplan |
|
|
Invention
|
Treatment of myasthenia gravis with zilucoplan. The present disclosure provides methods of using ... |
|
2022
|
Invention
|
Cyclic polypeptides for pcsk9 inhibition. Provided herein are cyclic polypeptide compounds that c... |
|
2021
|
Invention
|
Compositions and methods for microbial disease treatment. The present disclosure provides compoun... |
|
|
G/S
|
Pharmaceutical preparations, for human use, for the prevention and treatment of myasthenia gravis. |
|
|
G/S
|
Pharmaceutical preparations, for human use, for the
prevention and treatment of paroxysmal noctu... |
|
2020
|
Invention
|
Neurological disease treatment with complement inhibitors. The present disclosure provides method... |
|
|
Invention
|
Inflammatory disease treatment with complement inhibitors. The present disclosure provides method... |
|
|
Invention
|
Compositions and methods for modulating complement activity. [0281] Embodiments of the disclosure... |
|
|
Invention
|
Complement modulators and related methods.
The present disclosure presents compounds and composi... |
|
|
Invention
|
Complement modulators and related methods. The present disclosure presents compounds and composit... |
|
|
Invention
|
Modulators of complement activity.
The present disclosure provides compounds, compositions, and ... |
|
|
Invention
|
Zilucoplan as deep tissue penetrating c5 inhibitor. The disclosure relates to a method of treatin... |
|
|
Invention
|
Modulators of complement activity. The disclosure relates to a method of treating a complement-re... |
|
2019
|
Invention
|
Neurological disease treatment with zilucoplan.
Embodiments of the present disclosure include me... |
|
|
Invention
|
Neurological disease treatment with zilucoplan. The present disclosure relates methods of treatin... |
|
2018
|
Invention
|
Modulators of complement activity. The present disclosure provides methods of treating paroxysmal... |
|
|
Invention
|
Formulations for compound delivery.
The present disclosure provides formulations for sustained r... |
|
|
Invention
|
Formulations for compound delivery. The present disclosure provides formulations for sustained re... |
|
|
Invention
|
Peptide and peptidomimetic inhibitors. The present invention provides inhibitors and/or antagonis... |
|
2017
|
Invention
|
Modulators of complement activity. The present disclosure relates to polypeptide modulators of co... |
|
|
Invention
|
Ras binding peptides and methods of use. The present invention provides Ras modulators including ... |
|
2016
|
Invention
|
Modulators of complement activity. The present invention relates to a polypeptide inhibitor of co... |
|
|
Invention
|
Modulators of complement activity. The present invention relates to polypeptide modulators of com... |
|
|
G/S
|
Pharmaceutical research and development in the field of peptides and peptidomimetics |
|
|
G/S
|
Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of meta... |
|
|
Invention
|
Modulators of complement activity. The present invention provides polypeptide modulators of compl... |
|
|
G/S
|
Pharmaceutical research and development in the field of peptides and/or peptidomimetics; the fore... |
|
2015
|
Invention
|
Modulation of complement activity. The present invention provides modulators of complement activi... |
|
|
Invention
|
Modulation of complement activity. The present invention provides modulators of complement ... |
